A method for reducing renal tissue toxicity in a subject caused by a kidney damaging agent is disclosed. The method comprises administering to the subject: (i) a kidney damaging agent; and (ii) an inhibitor of glucose reabsorption.

The application relates to methods and systems for culturing individually selected cells in relative isolation from the rest of a population of cells, under physiologically relevant and controllable environmental conditions that can be designed to mimic specific environments, e.g., within a human body.

A method of making a live cell construct is carried out by: (a) providing a non-cellular support having a top surface and a bottom surface, (b) contacting live undifferentiated cells to the non-cellular support, and then (c) propagating a gastrointestinal epithelial cell monolayer on said top surface. In some embodiments, the live cells in the monolayer include: (i) undifferentiated cells (e.g., stem or progenitor cells); and (ii) optionally, but in some embodiments preferably, differentiated cells (e.g., enterocytes, Paneth cells, enteroendocrine cells, tuft cells, microcells, intra-epithelial lymphocytes, and/or goblet cells). Constructs formed by such methods and methods of using the same (e.g., in high through-put screening) are also described.

An object of the present invention is to provide an artificial tissue perfusion device capable of analyzing the interaction between a vascular cell layer and a parenchymal cell layer with high accuracy. An artificial tissue perfusion device includes a co-culture system (C) in which a plurality of types of cell are cultured. The co-culture system has a tubular well part (10) having a culture space (11) inside; a base material (20) having a perfusion flow path (26) which extends in a predetermined direction and is perfused with a medium, and a holding part (23) which opens to the perfusion flow path and holds the well part attachably and detachably; and a gel membrane (30) having a form of a porous membrane and disposed at an end portion of the well part facing the perfusion flow path in a case where the well part is held by the holding part. A tissue-based cell is cultured on a surface side of the gel membrane facing the culture space, and a luminal cell is cultured on a surface side of the gel membrane facing the perfusion flow path.

Systems and methods are provided including a housing configured to receive and engage a hollow tissue structure within a fluid chamber of the housing. A first pair of flow channels and a second pair of flow channels of the housing are fluidly coupled to the fluid chamber. The housing fluidly couples the first pair of flow channels and fluidly couples the second pair of flow channels via a second flow path such that a change in a fluid pressure differential between a first fluid in the first flow path and a second fluid in the second flow path deflects at least a portion of the hollow tissue structure causing a change in flow of the first fluid through the first pair of flow channels or a change in flow of the second fluid through the second pair of flow channels.

A method for characterizing contractions in cell cultures of contractile cells, the method comprising: acquiring a series of images of the contractile cells; for each image in the series of images, computing a movement index characterizing the rate of change in mean absolute pixel intensity variations across the whole image; and using the movement index to assess the contractions of the contractile cells. Also, applications of the method to the study of cardiac tissue analogs and other cell cultures, and a culture system used to implement the method.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The present invention provides apparatus and methods for production of tissue structures, organs, vaccines, and antibody products. In some examples, a cleanspace facility may be equipped with fluid interconnections and controls. The fluid interconnections may be located in a primary cleanspace or peripheral to a primary cleanspace. Sterilization may be performed within the primary cleanspace and within the fluid interconnections. In some examples, the facility may include modelling hardware and software, nanotechnology and microelectronic apparatus, and additive manufacturing equipment to print cells and support matrix to allow cells to grow into tissue structures and organs. Novel structures combining various cell types and electronics may be formed with the fabricator. In some examples, advanced vaccine products may be produced entirely within the scalable, sterile, and automated fabricator.

Disclosed herein are improved methods for fabricating bioprinted, three-dimensional, biological tissues. The methods relate to exposures to low temperatures, incubations at low temperatures of various durations, and fabrication in environments without structural cross-linking treatments.